KOSPIBiotech & Pharma234080

Jw Lifescience

₩11,050▼ 0.09%2026-10-02 close

Market Cap

₩174.7B

Turnover

₩37,579,905

Volume

3,409 shares

Shares out.

15.8M

PER

6.7×

PBR

0.8×

EPS

₩1,680

Dividend Yield

4.88%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩550 per share · Prices as of the 2026-10-02 close

Report overview

Infusion Market Leader Faces FX Test Amid Earnings Recovery

JW Life Science has expanded its top line on the back of its number-one position in Korea's infusion solution market and growth in total parenteral nutrition (TPN), but its reliance on imported raw materials and currency swings continue to drive quarter-to-quarter margin volatility.

1
The company leads Korea's infusion market with roughly 50% share in basic solutions and about 40% in nutritional solutions, competing in a three-way race with HK inno.N and Chosun Pharm.
2
2025 consolidated revenue rose 15.9% year-on-year to KRW 257.8 billion, but operating profit fell to KRW 33.2 billion, reflecting cost pressure.
3
Operating profit ranged between KRW 7.0 billion and KRW 9.3 billion across the four quarters from 2025Q3 to 2026Q2, while 2025Q2 owners' net profit of KRW 11.18 billion notably exceeded that quarter's operating profit of KRW 9.38 billion, pointing to a one-off item.
4
Infusion solutions are classified as essential medicines and are excluded from the government's generic price-cut policy, a factor cited as a relative stability advantage within the sector.
5
A weaker Korean won raises the cost of imported raw materials such as amino acids, which is flagged as the key swing factor for margins.

Business structure

JW Life Science is an infusion solution specialist producing basic solutions (electrolytes, glucose), total parenteral nutrition (TPN, marketed as Winuf), specialty solutions, nutritional solutions, and hemodialysis concentrates (HEMO).

Roles within the JW Group are clearly divided: JW Life Science handles development and manufacturing, affiliate JW Pharmaceutical handles domestic sales, and holding company JW Holdings manages overseas exports.

Basic solutions are designated as essential medicines under Korea's national health insurance reimbursement scheme, which only covers cost levels and results in thin margins, while TPN and nutritional solutions carry separately recognized pricing and higher profitability.

Through a global partnership, the company has an exclusive license-out and export agreement with Baxter International, the world's largest infusion solution maker, for its three-chamber TPN product Winuf (exported as Finomel) into the European market, and it became the first Asian company to obtain EU-GMP certification for TPN production facilities.

Building on this track record, the company states it is also pursuing US FDA cGMP certification to enter the American market. Subsidiary JW Bioscience complements the portfolio by supplying in-vitro diagnostic devices and non-reimbursed nutritional solutions.

Korea's infusion market remains an oligopoly among JW Life Science, HK inno.N, and Chosun Pharm, with rivals also expanding production capacity to compete for share.

Earnings trend

Quarterly revenue · Operating profit

₩62.3B₩9.4B25Q2₩62.6B₩7.1B25Q3₩64.3B₩7.6B25Q4₩63.5B₩9.3B26Q1₩63.2B₩9.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩188.9B₩27.1B2022₩206.9B₩30.9B2023₩222.5B₩35.9B2024₩257.8B₩33.2B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩62.3B	₩9.4B	15.1%
2025Q3	₩62.6B	₩7.1B	11.3%
2025Q4	₩64.3B	₩7.6B	11.8%
2026Q1	₩63.5B	₩9.3B	14.7%
2026Q2	₩63.2B	₩9.3B	14.8%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩188.9B	₩27.1B	₩15B	14.3%	10.7%	80.2%
2023	₩206.9B	₩30.9B	₩28.1B	14.9%	17.7%	60.5%
2024	₩222.5B	₩35.9B	₩44B	16.1%	21.9%	62.3%
2025	₩257.8B	₩33.2B	₩28.6B	12.9%	13.0%	44.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21

Earnings analysis

Annual revenue grew steadily from KRW 188.9 billion in 2022 to KRW 206.9 billion in 2023, KRW 222.5 billion in 2024, and KRW 257.8 billion in 2025.

Operating margin improved from 14.3% in 2022 to 14.9% in 2023 and 16.1% in 2024, before slipping back to 12.9% in 2025, a pattern consistent with both the consolidation of subsidiary JW Bioscience expanding the top line and rising cost pressure.

Owners' net profit rose from KRW 15.0 billion in 2022 to KRW 28.1 billion in 2023 and KRW 44.0 billion in 2024, then declined to KRW 28.6 billion in 2025.

On a quarterly basis, 2025Q2 revenue of KRW 62.26 billion and operating profit of KRW 9.38 billion were accompanied by owners' net profit of KRW 11.18 billion that exceeded operating profit, suggesting a one-off gain, while 2025Q3 profit fell sharply to operating profit of KRW 7.08 billion and net profit of KRW 4.87 billion on revenue of KRW 62.61 billion.

Profitability then recovered, with operating profit of KRW 7.58 billion in 2025Q4, KRW 9.32 billion in 2026Q1, and KRW 9.35 billion in 2026Q2.

Owners' net profit across the trailing four quarters (2025Q3-2026Q2) totaled approximately KRW 26.0 billion, below full-year 2024 (KRW 44.0 billion) but improved from the 2025Q2-Q3 trough.

Operating cash flow rose from KRW 14.1 billion in 2022 to KRW 37.6 billion in 2023 and KRW 50.7 billion in 2024, before easing slightly to KRW 40.5 billion in 2025, while the debt ratio declined markedly from 80.2% in 2022 to 44.3% in 2025, indicating an improving balance sheet.

Industry analysis

Korea's infusion solution market is in a structural growth phase driven by an aging population, rising hospitalization and length-of-stay, and growing numbers of cancer and gastrointestinal dysfunction patients that boost demand for total parenteral nutrition (TPN).

The market is an oligopoly of three players — JW Life Science, HK inno.N, and Chosun Pharm — with JW Life Science leading with roughly 50% share in basic solutions and about 40% in nutritional solutions.

HK inno.N has been accelerating its pursuit by expanding nutritional-solution capacity at its Osong plant, while Chosun Pharm, Korea's original infusion maker, continues steady growth, intensifying overall competition.

Basic solutions are designated as reimbursement-protected essential medicines with thin margins, while TPN and nutritional solutions carry separately recognized pricing and are classified as higher value-added products, making them the focus of capacity expansion races among producers.

The essential-medicine classification that exempts infusion solutions from the government's generic price-cut policy is cited as a relative source of stability for the sector.

However, given the industry's heavy reliance on imported raw materials such as amino acids, KRW/USD exchange rate swings directly affect cost of goods sold and operating profit — a risk common to all producers in the space.

Outlook

Sangsangin Securities projected in a May 2026 report that JW Life Science's 2026 consolidated revenue would rise 6.2% year-on-year to KRW 273.9 billion, with operating profit up 7.1% to KRW 35.6 billion, as growth in higher-margin products offsets cost pressure from a weaker won.

The same report estimated TPN revenue growing from KRW 84.8 billion in 2025 (up 11.7%) to KRW 90.1 billion in 2026 (up 6.3%), and nutritional-solution revenue rising from KRW 19.0 billion in 2025 (up 25.8%) to KRW 20.2 billion in 2026 (up 6.1%), while specialty-solution sales — which had declined in 2025 due to a high base — were expected to return to growth in 2026.

The company has been considering installing cogeneration or self-generation power facilities to reduce energy costs in infusion manufacturing and has pursued a related addition to its corporate purpose clause, suggesting a medium-term push to improve its cost structure.

The company also states it is targeting US FDA cGMP certification to enter the American market following its European export track record, which, if achieved, could broaden its overseas revenue base beyond Europe.

Sangsangin Securities estimated 2026Q1 consolidated revenue at KRW 72.1 billion (up 5.0% year-on-year) and operating profit at KRW 9.4 billion (up 1.8%), projecting stable performance once the boost from JW Bioscience's consolidation normalizes.

Valuation

PER

6.7×

PBR

0.8×

ROE

11.9%

EPS

₩1,680

BPS

₩14,638

Dividend per share

₩550

Valuation metrics have moved in tandem with the earnings recovery trajectory.

Since owners' net profit rose from 2022 through 2024, dipped in 2025, and then showed improvement over the trailing four quarters relative to its trough, the underlying earnings base used to derive per-share metrics appears to be in a turning phase.

Given that shareholders' equity has grown steadily each year (from KRW 140.3 billion in 2022 to KRW 220.6 billion in 2025), the price-to-book ratio should be read as a relative relationship between the pace of net asset growth and share price movement rather than a fixed level.

Sangsangin Securities, in a May 2026 report, issued a buy rating with a target price of KRW 18,000, citing stable earnings growth and dividend appeal. On dividends, the company has maintained a consistent annual cash dividend policy, a factor cited as having persisted despite earnings volatility.

That said, such brokerage forecasts and target prices reflect a judgment at a specific point in time and may change with actual supply-demand dynamics and market conditions.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21

Bull factors

Market Dominance and Policy Protection

JW Life Science holds a leading position in Korea's infusion market with roughly 50% share in basic solutions and about 40% in nutritional solutions.

Because infusion solutions are classified as essential medicines exempt from the government's generic price-cut policy, the company is seen as having a relatively stable revenue base within the sector. Decades of accumulated manufacturing know-how and Korea's largest production facilities also serve as entry barriers.

Growth in High-Margin TPN Products

Rising numbers of cancer and gastrointestinal dysfunction patients amid an aging population continue to drive TPN demand, with Sangsangin Securities projecting TPN revenue to grow 6.3% year-on-year in 2026.

TPN and nutritional solutions carry separately recognized pricing and higher profitability than basic solutions, so an increasing share of these products could support overall margin improvement.

Global Partnerships and New Market Entry

Through an exclusive license-out agreement with Baxter International, the company supplies Winuf (marketed as Finomel) to the European market and became the first Asian company to obtain EU-GMP certification for TPN production facilities.

Building on this capability, the company states it is pursuing US FDA cGMP certification to enter the American market, which could expand its export base if realized.

Bear factors

FX-Driven Cost Pressure

Because core raw materials such as amino acids are entirely imported, a weaker Korean won directly raises the cost-of-goods ratio.

Cost pressure is seen as a factor behind the decline in operating margin to 12.9% in 2025 despite higher revenue, and Sangsangin Securities also flagged rising exchange rates as a profitability variable for 2026.

Intensifying Competition and Low-Margin Basic Solutions

HK inno.N continues to expand nutritional-solution capacity at its Osong plant in pursuit of market share, while Chosun Pharm also maintains steady growth, intensifying competition within the oligopoly.

Basic solutions, designated as reimbursement-protected essential medicines with low profitability, still account for a substantial share of revenue, which could constrain overall margin improvement.

Quarterly Earnings Volatility

Owners' net profit of KRW 11.18 billion in 2025Q2 notably exceeded that quarter's operating profit of KRW 9.38 billion, while net profit fell sharply to KRW 4.87 billion in 2025Q3, illustrating significant quarter-to-quarter variability.

Such volatility could recur due to one-off items or FX and cost variables, warranting caution when reading trends.

Risk factors

Foreign Exchange Risk

Heavy reliance on imported core raw materials means a weaker won directly raises the cost-of-goods ratio. In 2022, during a period of sharp currency depreciation, operating profit declined despite revenue growth, illustrating that continued FX volatility could affect margin direction.

Competitive and Policy Risk

Ongoing capacity expansion by competitors such as HK inno.N sustains market-share competition, and any future changes to pricing or reimbursement policy for non-covered nutritional solutions could affect the profitability of higher-margin product lines.

Raw Material Supply Risk

Because core raw materials such as amino acids are sourced entirely from overseas, any disruption to global supply chains or a sharp rise in raw material prices could affect production and costs.

What to watch next

November 2026
Preliminary 2026Q3 earnings are expected to be disclosed around this time, warranting a check on TPN/nutritional solution growth rates and FX-driven changes in cost pressure.
December 2026
This is the time to check the year-end dividend record date and any disclosure on dividend policy, with attention on whether the prior year's dividend policy is maintained or changed.
Around March 2027 Annual General Meeting
It will be necessary to confirm whether the cogeneration/self-generation facility investment agenda is executed and whether concrete investment plans are finalized.
Fourth quarter of 2026
It is worth monitoring for progress updates or additional disclosures regarding the pursuit of US FDA cGMP certification.

Overall view

JW Life Science has a structurally stable business foundation built on its number-one position in Korea's infusion market, TPN growth, and the policy protection afforded by essential-medicine status.

However, as 2025 results showed, reliance on imported raw materials and FX volatility remain key variables driving quarterly margin swings, with periods such as 2025Q2-Q3 showing sharp profit fluctuations.

The key questions for 2026 are whether TPN- and nutritional-solution-driven revenue growth continues as brokerages project, and whether margin improvement is sufficient to offset cost pressure.

Medium-term variables worth monitoring include competitors' capacity expansions and the company's pursuit of US FDA cGMP certification for market entry. Ahead of any investment decision, it would be useful to check upcoming quarterly earnings disclosures and confirmation of dividend policy.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.